ArticleFrontiers in oncology2025
Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Combination therapy comprising ipilimumab and nivolumab is a safe and effective treatment for advanced renal cell carcinoma (RCC). However, its use in papillary RCC (pRCC) with an inferior vena cava (IVC) tumor thrombus extending to the right atrium has not been reported. Herein, we describe a case of pRCC with an IVC tumor thrombus extending to the right atrium and multiple metastases, which was effectively treated with combination therapy comprising ipilimumab and nivolumab. Methods: A 74-year-old man was diagnosed with pRCC based on a computed tomography-guided biopsy of a left renal tumor. The tumor extended to the right atrium and was accompanied by metastases to the pancreas, retroperitoneum, lymph nodes, bones, and lungs (cT3cN2M1). Based on the International Metastatic Database Consortium risk classification, the case was categorized as poor risk. Therefore, combination therapy comprising ipilimumab and nivolumab was initiated. Results: Nine months after initiating treatment, all metastases had disappeared, enabling open cytoreductive nephrectomy that had been deferred. Histopathological analysis revealed necrosis in most of the tumor tissue, with no viable cells in the primary tumor and IVC tumor thrombus. At 24 months postoperatively, the patient remained recurrence-free. Discussion: This case highlights the potential efficacy of preoperative combination therapy with ipilimumab and nivolumab in advanced pRCC with IVC tumor thrombus and distant metastases. The treatment achieved a complete response and allowed successful surgical resection, suggesting its potential as a viable option in similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.